External Media Coverage
This episode is produced and published by Harvard Business School / HBR Presents. Wootomatic hosts this embedded stream for educational and commentary purposes.
Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?
Hosted by Brian Kenny / Harvard Business Review
Could a New Business Model Make Clinical Drug Trials More Accessible to Patients?
Episode Summary
Dr. Brian Alexander at the Dana-Farber Cancer Center in Boston was in the process of launching a new type of clinical trial: an adaptive platform trial. Unlike the traditional randomized controlled trial, adaptive platform trials facilitate simultaneously studying multiple therapies for a given disease and have the potential to make clinical trials for new cancer drugs more efficient and accessible to patients. Developing questions around design, operations, and financing set the stage for this discussion with Harvard Business School professor Ariel Stern about her case: "Adaptive Platform Trials: The Clinical Trial of the Future?"
Inspired by HBS Case Studies?
Turn enterprise-grade growth strategies into real-time operational automations. Wootomatic builds custom AI agents, CRM funnels, and Zapier workflows on a flexible monthly subscription.